Skip to content

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03752476
Acronym
INOR Blact
Enrollment
1300
Registered
2018-11-26
Start date
2019-01-01
Completion date
2019-05-01
Last updated
2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Resistant Infection, Bacterial Resistance, Beta Lactam Resistant Bacterial Infection, Resistant Infection

Keywords

antibiotic resistant, multidrug resistant, Beta lactam

Brief summary

This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study. Cases are colonized patient by multidrug resistant bacteria hospitalized in intensive care during the fist hospitalization in intensive care. Temoin are patients with the same characteristics than case but no colonized by multidrug resistant bacteria.

Detailed description

The emergence of multidrug resistant is a wordwide problem. B lactam resistant increase. The antibiotic prescription impact this problem. B lactam antibiotic is prescribed everyday in intensive care unit. The switch of antibiotic is common. Antibiotic classes inclue a lot of rank with different spectum that impact the occurrence of resistant.

Interventions

PROCEDUREnumber of Beta lactam class prescription for the same infection

Each number of Beta lactam prescription without interruption are compared

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* all patient hospitalized more than 48 hours in intensive care unit in Besançon between january 2016 and december 2017

Exclusion criteria

* patient under guardianship * patient allergic to Beta lactam * colonization with mutidrug resistant the first week of hospitalization in intensive care unit

Design outcomes

Primary

MeasureTime frame
number of Beta lactam class prescription3 months

Contacts

Primary ContactESTELLE DOSSOT
estelle.dossot@gmail.com+33645578372

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026